InxMed (Shanghai)

InxMed (Shanghai), based in Nanjing, China, is a biotechnology company. InxMed is an oncology-focused biopharmaceutical company developing small molecules, antibodies and antibody-drug conjugates targeting tumour defence mechanisms. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing IN10018, KN046, Furmonertinib, D1553 and IN10018（Ifebemtinib） in pancreatic ductal adenocarcinoma, ovarian cancer, non-small-cell lung cancer and small-cell lung cancer. The largest, NCT07174908 (A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation), plans to enrol 400 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.